Details for Patent: 10,610,485

Which drugs does patent 10,610,485 protect, and when does it expire?

Patent 10,610,485 protects XATMEP and is included in one NDA.

This patent has three patent family members in three countries.

Summary for Patent: 10,610,485

Title:	Methotrexate composition
Abstract:	A Methotrexate composition for oral administration is provided comprising a pharmaceutically acceptable salt of Methotrexate and an aqueous carrier agent. The Methotrexate salt is substantially or completely soluble in the aqueous carrier agent, forming an aqueous solution. There is also provided a method of manufacturing a Methotrexate composition for oral administration, comprising mixing a pharmaceutically acceptable salt of Methotrexate with an aqueous carrier agent until the Methotrexate salt is substantially or completely soluble in the carrier agent to form an aqueous solution.
Inventor(s):	Carl Tierney, Stacey Powell, Peter Braybrooke, Geraint Jones
Assignee:	Rosemont Pharmaceuticals Ltd
Application Number:	US16/266,305
Patent Claim Types: see list of patent claims	Composition; Dosage form;

Drugs Protected by US Patent 10,610,485

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Azurity	XATMEP	methotrexate sodium	SOLUTION;ORAL	208400-001	Apr 25, 2017		RX	Yes	Yes			Y

Foreign Priority and PCT Information for Patent: 10,610,485

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	1200192.1	Jan 6, 2012

International Family Members for US Patent 10,610,485

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2614814
Spain	2726524
United Kingdom	201200192